DNAnexus names Laur as CEO

Bioinformatics company  DNAnexus Inc. named Thomas Laur as CEO and a director. Laur succeeds CEO Richard Daly, who will remain with the company as a board member and adviser. Laur joins DNAnexus from the technology enabled services division at Change Healthcare, now part of UnitedHealth Group Inc. (NYSE:UNH), where he was EVP and president.

Cargo Therapeutics Inc., which is developing a CAR T cell therapy targeting CD22, hired Michael Ports as CSO. Ports was VP and head of cell therapy discovery at Janssen Pharmaceuticals and also worked at Juno Therapeutics Inc., Celgene Corp. and Bristol Myers Squibb Co. (NYSE:BMY)...